2. MAPK/ERK Pathway Stem Cell/Wnt Immunology/Inflammation
  3. p38 MAPK ERK Interleukin Related
  4. Cavidine

Cavidine ((+)-Cavidine) is an analgesic and anti-inflammatory agent. Cavidine can be isolated from Corydalis ternata f. yanhusuo (Y.H.Chou & Chun C.Hsu) Y.C.Zhu. Cavidine reduces the expression of inflammatory factors IL-1β, IL-6 and TNF-α, and inhibits calcium ion influx. Cavidine inhibits the phosphorylation of p38 and ERK1/2. Cavidine increases mechanical and thermal pain thresholds in chronic pain models. Cavidine can be used for the research of chronic pain.

For research use only. We do not sell to patients.

Cavidine

Cavidine Chemical Structure

CAS No. : 32728-75-9

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Cavidine Related Antibodies

Top Publications Citing Use of Products

View All p38 MAPK Isoform Specific Products:

View All Isoforms
p38 MAPK Akt1 p38α p38β MAPK13 p38δ p38γ

View All ERK Isoform Specific Products:

View All Isoforms
ERK ERK1 ERK2 ERK5 ERK8

View All Interleukin Related Isoform Specific Products:

View All Isoforms
IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22 IL-18

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Cavidine ((+)-Cavidine) is an analgesic and anti-inflammatory agent. Cavidine can be isolated from Corydalis ternata f. yanhusuo (Y.H.Chou & Chun C.Hsu) Y.C.Zhu. Cavidine reduces the expression of inflammatory factors IL-1β, IL-6 and TNF-α, and inhibits calcium ion influx. Cavidine inhibits the phosphorylation of p38 and ERK1/2. Cavidine increases mechanical and thermal pain thresholds in chronic pain models. Cavidine can be used for the research of chronic pain[1].

IC50 & Target[1]

p38

 

ERK1

 

ERK2

 

IL-1β

 

IL-6

 

In Vitro

Cavidine (10 μg/mL) inhibits α,β-ME-ATP-induced calcium ion influx in P2X3-overexpressing U373 cells[1].
Cavidine (2.5-10 μg/mL; 24 h) inhibits LPS-induced activation of BV-2 microglial cells[1].
Cavidine (5-10 μg/mL) inhibits α,β-ME-ATP-induced phosphorylation of p38 and ERK1/2 in primary DRG neurons[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cavidine Related Antibodies
In Vivo

Cavidine (2.5-10 mg/kg; i.p.; daily; 7 days) exerts dose-dependent analgesic and anti-inflammatory effects in CFA-induced chronic inflammatory pain mice by downregulating P2X3 receptors, inhibiting microglial activation, suppressing inflammatory factor production, and reducing MAPK pathway activation[1].
Cavidine (2.5-10 mg/kg; i.p.; daily) exerts dose-dependent analgesic and anti-inflammatory effects in SNI-induced neuropathic pain mice by downregulating P2X3 receptors, inhibiting microglial activation, suppressing inflammatory factor production, and reducing MAPK pathway activation[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6 J (female, 6-9 weeks old, 20-25 g, CFA-induced)[1]
Dosage: 2.5 mg/kg; 5 mg/kg; 10 mg/kg
Administration: i.p.; daily; 7 days
Result: Significantly increased paw withdrawal threshold (PWT) and thermal withdrawal latency (TWL) compared to untreated CFA mice (P < 0.05, P < 0.01, or P < 0.001).
Reduced paw swelling compared to untreated CFA mice after 7 days of treatment (P < 0.05 or P < 0.001).
Suppressed DRG protein expression of IL-1β and TNF-α (P < 0.001), while 5 mg/kg and 10 mg/kg suppressed DRG IL-6 protein expression (P < 0.01 or P < 0.001).
Suppressed DRG mRNA expression of IL-6 (P < 0.001); 5 mg/kg and 10 mg/kg suppressed DRG mRNA expression of IL-1β (P < 0.001), and 10 mg/kg suppressed DRG mRNA expression of TNF-α (P < 0.001).
Suppressed spinal cord protein and mRNA expression of IL-1β, TNF-α, and IL-6 (P < 0.05 or P < 0.001).
Reduced spinal cord IBA-1 expression at 5 mg/kg and 10 mg/kg compared to untreated CFA mice (P < 0.05 or P < 0.01).
Reduced inflammatory cell infiltration and attenuated neuronal atrophy in DRG, as well as reduced neuronal vacuolation and glial clusters in the spinal cord compared to untreated CFA mice.
Suppressed DRG and spinal cord P2X3 receptor protein and mRNA expression (P < 0.05, P < 0.01, or P < 0.001).
Reduced DRG p-p38 and p-ERK1/2 phosphorylation at 2.5 mg/kg; 5 mg/kg and 10 mg/kg significantly suppressed both p-p38 and p-ERK1/2 phosphorylation in DRG (P < 0.001).
Animal Model: C57BL/6 J (female, 6-9 weeks old, 20-25 g, SNI-induced)[1]
Dosage: 2.5 mg/kg; 5 mg/kg; 10 mg/kg
Administration: i.p.; daily
Result: Significantly increased paw withdrawal threshold (PWT) and thermal withdrawal latency (TWL) compared to untreated SNI mice (P < 0.05, P < 0.01, or P < 0.001).
Suppressed DRG protein expression of IL-6 and IL-1β at 5 mg/kg and 10 mg/kg (P < 0.001), while 10 mg/kg suppressed DRG TNF-α protein expression (P < 0.01).
Suppressed spinal cord TNF-α protein expression at 2.5 mg/kg (P < 0.001); 5 mg/kg and 10 mg/kg suppressed spinal cord protein expression of TNF-α, IL-6, and IL-1β (P < 0.001).
Suppressed DRG mRNA expression of TNF-α (P < 0.001); 5 mg/kg and 10 mg/kg suppressed DRG mRNA expression of IL-6 and IL-1β (P < 0.01 or P < 0.001).
Suppressed spinal cord mRNA expression of IL-6 and IL-1β (P < 0.01 or P < 0.001); 5 mg/kg and 10 mg/kg suppressed spinal cord TNF-α mRNA expression (P < 0.01 or P < 0.001).
Reduced spinal cord IBA-1 expression at 5 mg/kg and 10 mg/kg compared to untreated SNI mice (P < 0.05 or P < 0.01).
Reduced inflammatory cell infiltration and attenuated neuronal atrophy in DRG, as well as reduced neuronal vacuolation and glial clusters in the spinal cord compared to untreated SNI mice.
Suppressed DRG and spinal cord P2X3 receptor protein expression at 5 mg/kg and 10 mg/kg (P < 0.05 or P < 0.01); all doses suppressed DRG and spinal cord P2X3 receptor mRNA expression (P < 0.001).
Reduced DRG p-p38 phosphorylation at 2.5 mg/kg; 5 mg/kg and 10 mg/kg significantly suppressed both p-p38 and p-ERK1/2 phosphorylation in DRG (P < 0.001).
Molecular Weight

353.41

Formula

C21H23NO4
CAS No.
SMILES

C[C@H]1C(C=C2)=C(C3=C2OCO3)CN4CCC5=CC(OC)=C(OC)C=C5[C@@]14[H]
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Cavidine Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Cavidine32728-75-9(+)-Cavidinep38 MAPKERKInterleukin RelatedExtracellular signal regulated kinasesILprimary DRG neuronsMAPK signalingcalcium ion influxTNF-αP2X3 receptorBV-2 microglial cellsU373 cellsIL-1βIL-6microglial activationInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Cavidine
Cat. No.:
HY-101546A
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.